Targeted therapy for breast cancer uses drugs designed to find and attack specific proteins or genes that help cancer cells grow, while largely sparing healthy tissue. Unlike chemotherapy, which kills fast-dividing cells throughout the body, targeted drugs zero in on the molecular features that make a particular cancer tick. The result is often fewer side effects and, for many patients, better outcomes. Which targeted therapy you receive depends on the biological makeup of your tumor, determined through testing for specific markers like HER2, hormone receptors, BRCA mutations, and others.
How Targeted Therapy Differs From Chemotherapy
Chemotherapy works broadly. It damages cells that divide quickly, which includes cancer cells but also hair follicles, the gut lining, and bone marrow. That’s why it causes hair loss, nausea, and a weakened immune system. Targeted therapy takes a different approach: it blocks the specific molecular signals that cancer cells depend on to survive, grow, and spread. By selectively disrupting those signals, targeted drugs can slow or stop tumor growth without doing as much collateral damage to normal cells.
That said, targeted therapy isn’t a complete replacement for chemotherapy. Many treatment plans combine both, using targeted drugs to hit cancer’s vulnerabilities while chemotherapy handles the rest. And in some cases, targeted agents are attached directly to chemotherapy molecules to deliver the toxic payload straight to cancer cells, a strategy called antibody-drug conjugates.
Biomarker Testing Determines Your Options
Before starting targeted therapy, your tumor is tested for specific biomarkers. In early breast cancer, the standard panel includes estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 (a marker of how fast cells are dividing). If you have HER2-negative breast cancer with a high risk of recurrence, testing for inherited BRCA1 and BRCA2 gene mutations is also recommended.
For advanced or metastatic breast cancer, the testing expands. Hormone-sensitive tumors are checked for PIK3CA mutations, which occur in roughly one-third of cases and open the door to a class of drugs called PI3K inhibitors. ESR1 mutations are tested after progression on first-line hormonal treatment. Triple-negative breast cancers are tested for PD-L1, a protein that helps determine whether immunotherapy might work. Rarer markers like NTRK gene fusions and microsatellite instability can also guide treatment in a small subset of patients.
This testing isn’t optional. Your biomarker profile is what determines which targeted therapies, if any, will be effective for your specific cancer.
HER2-Positive Breast Cancer Treatments
About 20% of breast cancers overexpress a protein called HER2, which drives aggressive tumor growth. HER2-positive breast cancer was historically one of the most difficult subtypes to treat, but targeted therapies have dramatically changed the outlook.
The foundational drug is trastuzumab, a monoclonal antibody that binds to the HER2 receptor on cancer cells, blocking the growth signals it sends and flagging the cell for destruction by the immune system. For larger tumors or in the pre-surgery setting, trastuzumab is often combined with pertuzumab, another antibody that targets a different part of the HER2 receptor to prevent it from pairing with other growth receptors. For patients whose cancer has progressed after initial treatment, margetuximab is an alternative antibody option used alongside chemotherapy.
Small-molecule drugs called tyrosine kinase inhibitors offer another angle. Lapatinib was the first approved for breast cancer and works by blocking signals inside the cell rather than on its surface. Tucatinib is a newer, more selective option that has shown particular promise for cancers that have spread to the brain.
Antibody-Drug Conjugates
One of the biggest advances in breast cancer treatment is the antibody-drug conjugate, or ADC. These drugs combine a targeting antibody with a potent cell-killing molecule, essentially using the antibody as a guided missile to deliver chemotherapy directly inside cancer cells. Once the ADC locks onto a cancer cell and gets pulled inside, the cell breaks down the antibody and releases the toxic payload. With certain ADC designs, the released drug can also leak out and kill neighboring cancer cells, a phenomenon called the bystander effect.
Four ADCs are currently FDA-approved for breast cancer. Trastuzumab emtansine (T-DM1) was the first, carrying a microtubule-disrupting agent attached to trastuzumab. Trastuzumab deruxtecan (T-DXd) is a newer and more potent ADC that carries roughly eight drug molecules per antibody compared to T-DM1’s average of 3.5. In December 2025, the FDA approved T-DXd in combination with pertuzumab as a first-line treatment for metastatic HER2-positive breast cancer, reflecting its growing role. Sacituzumab govitecan targets a different protein called TROP-2 rather than HER2, making it useful for triple-negative breast cancer. Datopotamab deruxtecan is the fourth approved ADC.
Hormone Receptor-Positive Breast Cancer Treatments
Hormone receptor-positive (HR+) breast cancer is the most common subtype and grows in response to estrogen or progesterone. While hormone-blocking therapy is the backbone of treatment, cancer cells can develop resistance over time. Targeted therapies are used alongside hormonal treatment to overcome or delay that resistance.
The most widely used targeted drugs for HR-positive breast cancer are CDK4/6 inhibitors. Cancer cells need to progress through a specific checkpoint in their growth cycle to divide, and CDK4 and CDK6 are the enzymes that push them through it. By blocking these enzymes, CDK4/6 inhibitors essentially freeze cancer cells in place, preventing them from multiplying. Three are FDA-approved: palbociclib, ribociclib, and abemaciclib. All three are taken as pills in combination with hormonal therapy.
When cancer progresses despite CDK4/6 inhibitors and hormonal treatment, the PI3K/AKT/mTOR signaling pathway is often to blame. Mutations in this pathway help cancer cells bypass hormonal blockade. Two drugs targeting this pathway are approved: alpelisib (a PI3K inhibitor for tumors with PIK3CA mutations) and capivasertib (an AKT inhibitor). These add another line of defense when first-line treatments stop working.
Triple-Negative Breast Cancer Options
Triple-negative breast cancer (TNBC) lacks estrogen receptors, progesterone receptors, and HER2 overexpression, which means it doesn’t respond to hormonal therapy or HER2-targeted drugs. For years, chemotherapy was the only systemic option. That’s changed.
For patients with inherited BRCA1 or BRCA2 mutations, PARP inhibitors offer a targeted approach. Your cells normally repair DNA damage through multiple pathways. BRCA genes are responsible for one of the most important repair mechanisms, called homologous recombination, which fixes dangerous double-strand DNA breaks. When BRCA genes are mutated, that repair pathway is already broken. PARP enzymes handle a different, simpler type of DNA repair. When you block PARP in a cell that also can’t perform homologous recombination, DNA damage accumulates to the point that the cancer cell can’t survive. Healthy cells, which still have working BRCA genes, can compensate. This makes PARP inhibitors selectively lethal to BRCA-mutated cancer cells.
The ADC sacituzumab govitecan, which targets the TROP-2 protein found on many triple-negative breast cancers, has also become an important treatment option for metastatic TNBC.
Side Effects to Expect
Targeted therapies generally cause fewer severe side effects than chemotherapy, but they aren’t side-effect-free. The specific effects depend on which drug you’re taking.
HER2-targeted therapies carry a risk of cardiac toxicity because heart muscle cells also express the HER2 receptor. This typically shows up as a decrease in the heart’s pumping efficiency and is usually reversible with early management. Regular heart function monitoring with echocardiograms is standard during treatment with trastuzumab and related drugs.
Skin reactions are common across several drug classes. Pertuzumab causes a mild rash in about 36% of patients. Alpelisib, the PI3K inhibitor, causes a rash in roughly 35%. PARP inhibitors can cause photosensitivity, making sun protection essential during treatment. Tyrosine kinase inhibitors, particularly when combined with certain chemotherapy drugs, are associated with hand-foot syndrome, a painful redness and peeling on the palms and soles.
CDK4/6 inhibitors have their own profile. Ribociclib requires regular heart rhythm monitoring because it can affect the electrical activity of the heart. All three CDK4/6 inhibitors can lower white blood cell counts, requiring periodic blood tests. Abemaciclib is more likely than the other two to cause diarrhea. The mTOR inhibitor everolimus commonly causes dry skin and itching.
Your care team will monitor for these effects with scheduled tests and adjust dosing as needed. Many side effects are manageable and don’t require stopping treatment.
How Treatment Is Given
Targeted therapies come in two main forms. Monoclonal antibodies like trastuzumab, pertuzumab, and margetuximab are given as intravenous infusions, typically at a cancer center on a set schedule (often every three weeks, though some formulations of trastuzumab are available as under-the-skin injections). ADCs are also delivered by infusion. These appointments can take anywhere from 30 minutes to a few hours depending on the drug and whether it’s your first dose.
Many other targeted therapies are pills you take at home. CDK4/6 inhibitors, tyrosine kinase inhibitors like tucatinib and lapatinib, PARP inhibitors, and PI3K/AKT inhibitors are all oral medications taken daily or on a specific cycle. This means fewer trips to the infusion center, though you’ll still need regular check-ins for blood work and monitoring.
Treatment duration varies widely. In early-stage breast cancer, HER2-targeted therapy with trastuzumab typically lasts about a year after surgery. For metastatic disease, targeted therapy often continues for as long as it’s working and side effects remain tolerable, which can mean months or years of treatment.